Theravia Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 50

Employees

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 2

  • Investments
  • 1

Theravia General Information

Description

Operator of a pharmaceutical company intended to develop and commercialize treatments for rare diseases. The company develops treatments related to hereditary metabolic diseases, hematology-oncology immunology and gene cell therapy, thereby providing patients with pharmacy products when their medical needs are unmet.

Contact Information

Website
www.theravia.com
Formerly Known As
Laboratoires CTRS Société Par Actions Simplifiée, Laboratoires CTRS SAS, CTRS Laboratoires, CTRS, Laboratoires CTRS, SAS, CTRS Laboratories, Laboratoires C.T.R.S.
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Private Equity-Backed
Corporate Office
  • 16, Rue Montrosier
  • 92200 Neuilly-Sur-Seine
  • France
+33 01
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Parent Company
Norgine
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 16, Rue Montrosier
  • 92200 Neuilly-Sur-Seine
  • France
+33 01

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Theravia Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Theravia‘s full profile, request access.

Request a free trial

Theravia Patents

  • 13

    Total Documents Applications and Grants

  • Total Patents Families

  • 5

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

Theravia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4132532-A1 Topical use of erlotinib for treating keratodermas in children Pending 07-Apr-2020
US-20230149405-A1 Topical use of erlotinib for treating keratodermas in children Pending 07-Apr-2020
WO-2021204843-A1 Topical use of erlotinib for treating keratodermas in children Inactive 07-Apr-2020
US-20220233478-A1 Pharmaceutical composition containing hydroxyurea for use in the treatment of severe chronic anemia Inactive 28-Feb-2019
US-20170071954-A1 Pediatric cholic acid formulation Inactive 16-Sep-2015 A61K9/0095
To view Theravia’s complete patent history, request access »

Theravia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Theravia Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Theravia‘s full profile, request access.

Request a free trial

Theravia Investments (1)

Theravia’s most recent deal was a Buyout/LBO with Addmedica for . The deal was made on 01-Jan-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Addmedica 01-Jan-2018 Buyout/LBO Pharmaceuticals
To view Theravia’s complete investments history, request access »

Theravia FAQs

  • When was Theravia founded?

    Theravia was founded in 2002.

  • Where is Theravia headquartered?

    Theravia is headquartered in Neuilly-Sur-Seine, France.

  • What is the size of Theravia?

    Theravia has 50 total employees.

  • What industry is Theravia in?

    Theravia’s primary industry is Drug Discovery.

  • Is Theravia a private or public company?

    Theravia is a Private company.

  • What is the current valuation of Theravia?

    The current valuation of Theravia is .

  • What is Theravia’s current revenue?

    The current revenue for Theravia is .

  • Who are Theravia’s investors?

    Merieux Equity Partners (Lyon) has invested in Theravia.

  • When was Theravia acquired?

    Theravia was acquired on 13-Aug-2025.

  • Who acquired Theravia?

    Theravia was acquired by Norgine.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process